1 Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal

2 route among adult who had received CoronaVac

3

4 Authors:

- 5 Rapisa Nantanee, MD^{a,b}, Puneyavee Aikphaibul, MD^{a,c}, Peera Jaru-Ampornpan, PhD^d, Pimpayao
- 6 Sodsai, PhD^e, Orawan Himananto, PhD^f, Tuangtip Theerawit, RN^a, Jiratchaya Sophonphan,
- 7 MSc^g, Punyot Tovichayathamrong, MD^h, Kasama Manothummetha, MD^h, Tysdi Laohasereekul,
- 8 MD^h, Narin Hiransuthikul, MD, PhDⁱ, Nattiya Hirankarn, MD, PhD^e, Thanyawee Puthanakit,
- 9 MD^a on behalf of the Study Team*

10

^aCenter of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University,

- 12 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- ^bPediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and
- 14 Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King
- 15 Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873, Rama IV Rd,
- 16 Pathumwan, Bangkok, 10330, Thailand
- ^c Division of Pediatric Dermatology, Department of Pediatrics, Faculty of Medicine,
- 18 Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross
- 19 Society, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- ^d Virology and Cell Technology Research Team, National Center for Genetic Engineering and
- 21 Biotechnology (BIOTEC)

- ^eCenter of Excellence in Immunology and Immune-mediated Diseases, Department of
- 23 Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan,
- 24 Bangkok, 10330, Thailand
- ¹^f Monoclonal Antibody Production and Application Research Team, National Center for Genetic
- 26 Engineering and Biotechnology (BIOTEC)
- ^g The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red
- 28 Cross AIDS Research Centre, Bangkok, Thailand
- ^h Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV
- 30 Rd, Pathumwan, Bangkok, 10330, Thailand
- ⁱ Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
- 32 University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- 33
- 34 Corresponding author: Thanyawee Puthanakit, MD
- 35 Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics,
- 36 Faculty of Medicine, Chulalongkorn University
- 37 1873, Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
- 38 Telephone: (+66)2-2564930
- 39 E-mail: thanyawee p@chula ac th
- 40 *Additional study team members are listed.

41

42 **Highlights**:

- Intradermal AZD1222 booster vaccine gave comparable short-term immunogenicity but
- 44 lower 90-day immunogenicity with conventional intramuscular vaccine.

- Lower systemic but higher local reactogenicity was found in intradermal AZD1222
- 46 booster vaccine.
- Blister and pruritus could be seen after intradermal AZD1222 booster vaccine.
- 48
- 49 Word counts: 3295, Abstract 300
- 50 41 References, 2 Tables, 3 Figures, 1 Supplementary Table, 1 Supplementary Figure
- 51 Thai clinical trial registry: TCTR 20210817003

52 Abstract

53 Background

- 54 Currently, booster dose is needed after 2 doses of inactivated COVID-19 vaccine. With limited
- 55 resource and shortage of COVID-19 vaccine, intradermal(ID) administration might be a potential
- 56 dose-sparing strategy.

57 **Objective**

- 58 To determine antibody response and reactogenicity of ID ChAdOx1 nCoV-19
- 59 vaccine(AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose
- 60 CoronaVac(SV) in healthy adult.

61 Methods

- 62 This is a prospective cohort study of adult aged 18-59 years who received 2-dose SV at 14-35
- 63 days apart for more than 2 months. Participants received ID AZD1222 at fractional low
- $dose(1 \times 10^{10} \text{ viral particles}, 0.1 \text{ ml})$. Antibody responses were evaluated by surrogate virus
- 65 neutralization test(sVNT) against wild type and delta variant and anti-spike-receptor-binding-
- 66 domain immunoglobulin G(anti-S-RBD IgG) at prior, day14 or 28, and day90 post booster.
- 67 Solicited reactogenicity was collected during 7 days post-booster. Primary endpoint was the
- differences of sVNT against delta strain \geq 80% inhibition at day14 and 90 compared with the
- 69 parallel cohort study of 0.5-ml intramuscular(IM) route.

70 **Results**

- From August2021, 100 adults with median(IQR) age of 46(41-52) years participated. At
- 72 baseline, geometric means(GMs) of sVNT against delta strain prior to booster were
- 73 22.4% inhibition (95% CI 18.7-26.9) and of anti-S-RBD IgG were 109.3 (95.4-125.1) BAU/ml.
- GMs of sVNT against delta strain were 92.9% inhibition (95% CI 87.7-98.3) at day14 and

75	73.1% inhibition (66.7-80.2) at day 90 post ID booster. The differences of proportion of
76	participants with sVNT to delta strain 280% inhibition in ID recipients versus IM were
77	+4.2%(95%CI-2.0to10.5) at day14, and -37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs
78	were 2037.1(95%CI1770.9-2343.2) at day14 and 744.6(650.1-852.9) BAU/ml at day90,
79	respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83-1.20) at day14,
80	and 0.82(0.66-1.02) at day90. Only 18% reported feverish, compared with 37% of IM(p=0.003).
81	Only 18% reported feverish, compared with 37% of IM(p=0.003). Common reactogenicity was
82	erythema(55%) at injection site while 7% reported blister.
83	Conclusion
84	Low-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared
85	with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity.
86	
87	Keywords: SARS-CoV2 vaccine, booster dose, AZD1222, Neutralizing antibody titer, anti-
88	SARS CoV2 IgG, CoronaVac vaccine, ChAdOx1 nCoV-19 vaccine, intradermal
89	
90	Abbreviations:
91	BAU = Binding-antibody unit
92	BMI = Body mass index
93	CMI = Cell-mediated immunity
94	ELISpot = Enzyme-linked immunospot
95	GM = Geometric mean
96	GMR = Geometric mean ratio

- 97 ID = Intradermal
- 98 IM = Intramuscular
- 99 PBMC = Peripheral blood mononuclear cell
- 100 SFU = Spot forming unit
- 101 S-RBD = Spike receptor binding domain
- 102 sVNT = Surrogate virus neutralization test

103 **1. Introduction**

104 Global report of Coronavirus disease (COVID-19) infection was over 250 million cases 105 with more than 5 million deaths [1], despite over 7 billion doses of vaccination have been 106 administered. In Thailand, as of November 2021, more than 2 million reported COVID-19 107 infection with over 20,000 deaths. Inactivated COVID-19 vaccine, CoronaVac (Sinovac Life 108 Sciences, Beijing, China), was used for mass vaccination in several countries e.g., Thailand, 109 China, Brazil, and Chile. Effectiveness of CoronaVac for prevention of COVID-19 was 65.9% 110 from study in Chile [2] and 36.8% from study in Brazil [3]. With the rising of delta variant 111 (B 1 617 2) of SAR-CoV-2 globally, the neutralizing activity induced by CoronaVac declined 112 [4] Hence, heterologous prime boost vaccination may provide better immunogenicity. With 113 AZD1222 followed by BNT162b2 heterologous prime boost vaccination, this vaccination 114 strategy provided highest T cell reactivity compared with homologous vaccination [5, 6]. 115 Standard administration of currently available COVID-19 vaccine is via intramuscular 116 injection. Routes for vaccine administration could be intramuscular (IM), intradermal (ID) in 117 which efficacy is related to the immunogenicity [7]. ID administration offers potential dose-118 sparing benefit compared with intramuscular administration, rabies vaccination as example. ID 119 vaccination is a technique in which the vaccine is administered into dermis which is rich in 120 antigen presenting cells such as dermal dendritic cells [8]. Because of the abundance of antigen 121 presenting cells in skin, ID administration required less antigenic dose (usually 20%-30% of 122 standard dose) to induce immune responses than standard IM vaccination. Many studies showed 123 effective immune response by ID vaccination including influenza, rabies, hepatitis B, Bacille 124 Calmette-Guerin (BCG), and polio vaccination [7, 9-12]. For influenza vaccine, a systematic 125 review and meta-analysis showed comparable seroprotection rates for 9-ug ID with 15-ug IM

Page 7 of 40

126 injection with higher local adverse event particularly erythema and swelling [9]. For rabies

- 127 vaccine, ID schedules offer advantages through savings in costs, doses and time as recommended
- 128 by WHO and also approved use on label of vaccine [12].
- 129 Fractionated-dose ID COVID-19 vaccine is the potential for rapid achievement of herd
- 130 immunity based on other vaccines reported [7]. Study of one-tenth dose of mRNA-1273 ID
- 131 vaccination showed comparable anti-spike IgG and anti-RBD IgG responses to conventional IM
- 132 vaccination at 2 weeks post primary vaccination series [13]. However, one-fifth dose of
- 133 BNT162b2 ID booster in healthy Thai adult post 2-dose CoronaVac failed to boost T cell
- response at 14 days, despite robust neutralizing antibodies response [14]. A case report of ID

135 AZD1222 after 2 doses of CoronaVac showed increase of antibodies and T cell responses against

136 spike protein which neutralizing antibody increased to almost 100% with minimal local reaction

- 137 at 2-3 weeks after booster [15].
- This study aims to evaluate immunogenicity and reactogenicity of ID AZD1222 booster
 dose in adults who had received 2 doses of CoronaVac.
- 140

141 **2. Methods**

142 **2.1 Study design and participants**

143 This study was conducted at Chulalongkorn University Health Center, Faculty of 144 Medicine, Chulalongkorn University, Bangkok Thailand. This is a prospective cohort study. The 145 participants who aged 18 - 59 years old and received two doses of CoronaVac for at least 60 146 days, 14 - 35 days apart were included in this study. The exclusion criteria were receiving any 147 immunosuppressants or blood products within 3 months before the enrollment or receiving any 148 vaccines within 2 weeks. All participants gave written informed consent prior to study 149 enrollment. 150 This study was registered in Thai Clinical Trials Registry (thaiclinicaltrials org, TCTR 151 20210817003). Immunogenicity parameters were compared with the parallel randomized 152 controlled trial on healthy adult with standard dose and low dose IM administration of AZD1222 153 booster after completing 2 doses of CoronaVac (TCTR20210722003), conducted at same 154 settings and lab. We compared the results of this study with conventional standard dose (0.5 ml) 155 IM group. Institutional review board of Faculty of Medicine, Chulalongkorn University 156 approved this study (IRB no. 663/64) and parallel IM AZD1222 booster study (IRB no. 600/64). 157

158 **2.2 Study procedures**

One hundred participants were recruited in this study. At baseline, the history of SARS-CoV-2 vaccination and exposure to confirmed case within 3 months were taken. Blood sample was collected prior to giving a booster dose. The participants received ID AZD1222 lot number A1009, manufactured by Siam Bioscience Co., Ltd., 0.1 ml (1 x 10¹⁰ viral particles). The vaccination was performed by trained physician/nurse (RN and TT). The solicited local and

164	systemic reactogenicity during 7 days after vaccination was recorded in the diary. The solicited
165	reactogenicity included fever, pain, swelling, erythema, headache, malaise, myalgia, arthralgia,
166	vomiting, and diarrhea. Scheduled visits were day 14 for 50 participants, day 28 for 50
167	participants. At day 90, 40 participants were scheduled, to collect reactogenicity data and
168	perform blood collection.
169	The cell-mediated immunity (CMI) sub study was performed among 20 participants, at
170	baseline, day 28, and day 90, with enzyme-linked immunospot (ELISpot) assay to evaluate T and
171	B cell responses.
172	
173	2.3 Immunogenicity outcomes
174	All participants' samples were tested for spike receptor binding domain (S-RBD) IgG,
175	and functional neutralizing antibody (NAb) against SARS-CoV-2 wild type and delta variants by
176	surrogate virus neutralization test (sVNT). All of the immunogenicity results in ID group were
177	compared with IM participants at equivalent time points.
178	
179	Quantitative spike receptor binding domain IgG (anti-S-RBD IgG) ELISA
180	The ELISA protocol was adapted from Amanat et al. (2020) [16]. Briefly, diluted serum
181	samples were incubated in 96-well plates coated with purified recombinant Myc-His-tagged S-
182	RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1). Then, ELISA was performed. Anti-
183	S-RBD IgG level was reported in binding-antibody units (BAU/mL) following conversion of
184	OD450 values with the standard curve using known units of WHO international standard
185	(NIBSC 20/136). We used anti-S-RBD IgG level at 506 BAU/ml, which is correlated with 80%
186	vaccine efficacy reported by the Oxford COVID vaccine trial group [17], as a cut off.

187

188 <u>Surrogate virus neutralization test (sVNT)</u>

A surrogate virus neutralization test was set up as previously described in Tan *et al.* (2020) [18]. Recombinant SRBD from the wild-type (Wuhan-Hu-1) and delta (B.1.617.2) strains
 were used. Serum samples - SRBD mixture were incubated in 96-well plates coated with 0.1
 µg/well recombinant human ACE2 ectodomain (GenScript). Then, ELISA was performed. The

193 negative sample was pre-2019 human serum. The % inhibition was calculated as follows:

%*inhibition* =
$$100 \times \left[1 - \frac{sampleOD450}{negativeOD450}\right]$$

194 *Enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses*

For T cell, ELISpot assay using a Human IFN-γ ELISpotProTM kit (Mabtech, Stockholm, 195 196 Sweden) was used for SARS-CoV-2-specific T cell responses in fresh peripheral blood mononuclear cells (PBMCs). Briefly, $2.5 \square \times \square 10^5$ PBMCs were stimulated in AIM-V medium 197 198 with overlapping peptide pool from 100 peptides of SARS-CoV-2 Spike (S) defined peptides and 199 101 peptides from the nucleoprotein (N), membrane protein (M), open reading frame proteins 200 (O) (Mabtech, Stockholm, Sweden) at a final concentration of $2 \mu g/ml$ for 20 hours. Negative 201 control and positive control, anti-CD3, were also included. The spots were counted using 202 ImmunoSpot analyzer. Spot counts for negative control wells were subtracted from the test wells 203 to generate normalized readings, these are presented as spot forming unit (SFU) per million 204 PBMCs. 205 For B cells, Human IgG SARS-CoV-2 RBD ELISpot PLUS (ALP) kit (Mabtech, 206 Stockholm, Sweden) was used for SARS-CoV-2-specific B cell responses. Briefly, the memory 207 B cells were differentiated into antibody secreting cells by pre-stimulating the fresh PBMCs with 208 R848 and IL-2 for 72 hours. Unstimulated well was also used as negative control. Stimulated and

209	unstimulated PBMCs (5 $\square \times \square 10^5$ cells per well) were added into ELISpot plate and incubated for
210	18 hours. An RBD-WASP antigen was added into RBD-specific IgG detected well while
211	MT78/145- biotinylated antibodies were added into total IgG detected well, positive control.
212	Anti-WASP-ALP was added into RBD-specific IgG detected well and negative control well
213	while streptavidin-ALP was added into total IgG detected well. Spot counting was performed in
214	the same method as T cells.
215	
216	2.4 Reactogenicity
217	Solicited reactogenicity was recorded by participants using diary. All symptoms were
218	graded in 3 grades [19]: grade 0 for no symptom; grade 1 for mild symptom, which was not
219	interfere with activities or vomiting $1 - 2$ times/day or diarrhea $2 - 3$ times/day; grade 2 for
220	moderate symptom, which interfered with activities or need to take medication, or vomiting
221	more than 2 times/day or diarrhea 4 – 5 times/day; grade 3 for severe symptom, which
222	incapacitated or need hospitalization or diarrhea 6 or more times/day. Fever was graded as grade
223	$1 (38.0 - 38.4^{\circ}C)$, grade $2 (38.5 - 38.9^{\circ}C)$, grade $3 (39 - 40^{\circ}C)$, and grade $4 (more than 40^{\circ}C)$.
224	Unsolicited adverse events were also recorded at all visits by study team.
225	
226	2.5 Statistical analysis
227	Demographic and clinical characteristics were described for the subjects. Continuous
228	variables were expressed as median (interquartile range: IQR) and number with percentage for

229 categorical variables. Differences in continuous and categorical variables between two groups

230 were assessed using a Wilcoxon rank sum test, Chi-square test, or fisher exact test, respectively.

The sVNT results, to either wild type or delta strain, of more than 80% were used to classify the

232	achievement of 80% protection against symptomatic infection. The anti-S-RBD IgG of more
233	than 506 BAU/ml were used in this study as a cut off for protective antibody level, which
234	previously reported to be associated with 80% vaccine efficacy against primary symptomatic
235	COVID-19 [20].
236	We presented primary comparisons between ID and IM group in terms of the differences of
237	proportion of participants achieving sVNT \geq 80% inhibition. Non-inferiority was concluded if the
238	lower bound of the 95% CI did not exceed -10%. Geometric means (GMs) and geometric mean
239	ratios (GMRs) with 95% confidence interval of anti-S-RBD IgG and sVNT, at day 0, 14, 28, and
240	90 after booster vaccination, were calculated. Non-inferiority was concluded if the lower bound
241	of the 95% CI did not exceed 0.67 for the GMR of anti-S-RBD. All P-values reported are two-
242	sided. Statistical significance was defined as P<0.05. Stata version 15.1 (Stata Corp., College
243	Station, Texas), was used for analysis.

245 **3. Results**

246 **3.1 Baseline characteristic**

247	The participants were enrolled during August 2021. The demographic data was shown in
248	Table 1. Median age was 46 (IQR 41-52) years, 55% were male. Underlying disease was
249	described, as shown in Table 1. Duration between 2 doses of CoronaVac was 21 days with
250	median 71 (IQR 65-76) days prior to ID booster administration. The sVNT against delta strain
251	GM was 44.5% inhibition and against wild type was 22.4% inhibition. The number of female
252	were higher in IM cohort, while the interval between completion of 2-dose CoronaVac and
253	AZD1222 booster was longer in ID than IM cohort.
254	
255	3.2 Reactogenicity
256	Most common solicited reactogenicity reported was localized at injection site such as
257	erythema and pain, as shown in Figure 1 and Supplementary Table 1. More than half (53%)
258	participants reported erythema, lasting for median duration of 4 (IQR 3-6) days, which was
259	mostly grade 1. Pain at injection site was reported in 43% with median duration of 2 (IQR 1-4)
260	days and mostly grade 1. Other solicited reactogenicity reported were 40% fatigue, 30% myalgia,
261	27% headache, 18% feverish, 17% swelling, 12% arthralgia and 9% diarrhea. Vesicle and blister
262	at injection site, which progressed to dry blister and turned to hyperpigmentation, were also
263	reported as unsolicited reactogenicity (photo as shown in Supplementary Figure 1).
264	Lower systemic reactogenicity including fever (0% ID versus 27% IM, $p = N/A$), feverish
265	(18% ID versus 37% IM, p = 0.003), headache (27% ID versus 64% IM, p <0.001), fatigue (40%
266	ID versus 68% IM, p <0.001), and myalgia (30% ID versus 69% IM, p <0.001) was reported in
267	ID compared with IM, as shown in Supplementary Table 1.

2	6	8
_	v	v

269 **3.3 Immunogenicity of ID booster**

- 270 3.3.1 sVNT
- 271 Ninety-eight percent of the participants achieved sVNT against delta strain and wild type
- \geq 80% inhibition at both day 14 and day 28. The GMs (95% CI) of sVNT to delta strain were
- 273 95.5% inhibition (94.2-96.8) at day 14, and 93.7% inhibition (91.9-95.5) at day 28 after ID
- booster, as shown in Figure 2 and Table 2. The GMs (95% CI) of sVNT to wild type were 94.8%
- 275 inhibition (94.0-95.6) at day 14, and 93.7% inhibition (92.1-95.4) at day 28, as shown in Table 2.
- 276 At day 90 post booster vaccination, the GMs of sVNT, to both delta strain and wild type, waned
- to 73.1% inhibition (66.7-80.2) and 81.9% inhibition (76.2-88.0), respectively.

278

279 3.3.2 Anti-S-RBD IgG

- 280 The GMs (95% CI) of anti-S-RBD IgG were 2037.1 (1770.9-2343.2), 1084.9 (970.0-
- 281 1213.4), and 744.6 (650.1-852.9) BAU/mL at day 14, 28, and 90 after ID booster, respectively,
- as shown in Table 2.

283

284 **3.4 Immunogenicity of ID compared with IM booster**

285 Proportion of participants with sVNT to delta strain ≥80% inhibition at day 14 was non-inferior

among ID recipients compared with IM recipients, with difference of 4.2% (95% CI -2.0 to

- 10.5). But at day 90, it was significantly lower, with difference of -37.3% (-54.2 to -20.3). These
- 288 differences were similar to sVNT to wild type, as shown in Table 2. GMR of anti-S-RBD IgG
- showed non-inferiority at day14, with GMR of 0.99 (0.83-1.20), and borderline inferior at day

- 290 90, with GMR of 0.82 (0.66-1.02). However, at 90 days after ID vaccination, only 79.5% had
- antibody exceeding the proposed protective level, compared with 83.8% of IM recipients.
- 292

293 **3.5 T and B cell responses evaluated by ELISpot assay**

- From the sub study analysis of CMI response, ELISpot assay showed significant rise of T
- cell and B cell response at day 28 and declined at day 90, as shown in Figure 3. Median (IQR) of
- 296 IFN-□-producing T cell spots specific to SNMO protein-derived peptide pools at day 0 was 32
- 297 (14-56), at day 28 was 146 (70-192), and at day 90 was 90 (20-140) SFU/10⁶ PBMCs,
- respectively. Compared with IM study, the median (IQR) was 52 (40-48) at day 0, 96 (44-128) at
- day 28, and 44 (32-72) SFU/10⁶ PBMCs at day 90, respectively. Median (IQR) of RBD-specific
- 300 memory B cell spots at day 0 was 2 (0-10), increased to 18 (14-36) at day 28, and declined to 6
- 301 (4-20) SFU/ 10^6 PBMCs at day 90. Compared with IM study of 4 (0-16) at day 0, 26 (16-32) at
- 302 day 28, and 8 (4-16) SFU/ 10^6 PBMCs at day 90.
- 303

304 4. Discussion

305 ID AZD1222 booster vaccine in 2-dose-CoronaVac-primed adults raised high anti-S-306 RBD IgG >506 BAU/ml, and high levels of functional neutralizing antibodies >80% inhibition 307 as measured by sVNT to wild type and delta strain, thus non-inferior to IM route at day 14. 308 However, at 3 months post ID AZD1222 booster vaccination, this study demonstrated, despite 309 similar anti-S-RBD IgG, but lower sVNT against delta strain to IM booster, suggesting more 310 rapid waning neutralizing antibody response after ID compared to IM route. Most reactogenicity 311 occurred locally with erythema, pain, and swelling at injection site. Erythema, swelling, and 312 blister were reported more common in ID booster. Systemic symptoms such as fever, feverish, 313 headache, fatigue, and myalgia were less common than conventional IM injection. 314 The non-inferior immunogenicity of ID vaccination was demonstrated for influenza, 315 rabies, and hepatitis B vaccines [21]. Immunogenicity of ID AZD1222 at day 14 was not inferior 316 to conventional IM booster vaccine as shown with GMR of anti-S-RBD and difference in 317 proportion of participants having sVNT to delta strain and wild type passing 80%. This 318 comparable result is similar to previous study in Netherland [22] which reported a robust 319 antibody response from ID administration of mRNA COVID-19 vaccine at day 43 with 320 comparable anti-spike IgG response for 10 µg ID with 100 µg IM mRNA-1273 vaccine. 321 Additionally, recent report from Thailand also denoted a fractional-dose BNT162b2 ID booster, 322 in healthy adults who had completed 2-dose inactivated vaccine for 2-3 months, induced 323 comparable antibody level and function to the conventional IM booster when assessed on day 14 324 and 28 [14]. To our knowledge, no published report demonstrated immunogenicity results at 3 325 months post ID AZD1222 booster vaccination, which this study demonstrated inferior 326 neutralizing antibodies.

327 Although, the importance of cellular immunity in correlation with vaccine protection is 328 still unclear, specific T cells have been reported to reduce the severity of SARS-CoV-2 infection 329 [23]. In this study, we have shown that a third dose of ID AZD1222 booster vaccine can 330 increase specific T cell responses slightly higher than conventional IM route, similar to the 331 previous report [24]. As opposed to previous ID BNT162b2 study, which failed to demonstrate T 332 cell response, suggesting different vaccine platforms might play a role in cellular immune 333 response. Specific memory B cells also have been reported to play a crucial role for effective 334 responses to infection [25, 26]. Our result showed the slight boost of B cell response at 1 month 335 and drop at 3 months, after ID AZD1222 booster. The timing of B cell study might be accounted 336 for these responses, since the previous study showed the detectable B cell response after 337 COVID-19 infection for 3-6 months [27].

338 This study reported local reactogenicity including erythema, blister, and pruritus after ID 339 AZD1222 booster vaccine which is similar to previous report on rabies inactivated vaccine that 340 more erythema and pruritus were reported from ID than conventional IM administration [28]. 341 Also blister formation was reported after BCG vaccination that evolved over two weeks into an 342 ulcer at injection site [29]. ID influenza vaccine study reported significant higher local adverse 343 events particularly erythema and swelling, and also more common of fever and chills which is 344 different from this study that fever was more common in IM vaccination [9]. Hyperpigmentation 345 was also reported in this study as still seen on day 28 follow up visit which previous study of 346 hepatitis B vaccine reported of local hyperpigmentation after ID vaccination in 55% [30]. 347 Compared with parallel cohort IM study, ID booster had more local reactogenicity (erythema and 348 swelling) at injection site but less pain and systemic reactogenicity (fatigue, myalgia, headache, 349 feverish, arthralgia and diarrhea).

As current situation of COVID-19 pandemic, more vaccine supply is still needed for 350 351 many countries as vaccine coverage is not enough to prevent mortality [31-33]. Almost half of 352 the world population has received at least one dose of COVID-19 vaccine but only 2.2% of 353 people in low-income countries have received vaccine [34]. AZD1222 or Astra Zeneca/Oxford 354 COVID-19 vaccine has been used in Europe since December 2020 and also distributed in many 355 countries including low to middle income countries [35]. As availability in many countries with 356 limited vaccine supply, the ID administration of AZD1222 might be considered for mass 357 vaccination as an advantage of dose-sparing technique [7]. However, there are some limitations, 358 needs of skilled health providers for administration [36], and more rapid waning of neutralizing 359 antibodies.

360 This study was limited by cohort study design without randomized control trial but there 361 was the parallel cohort study with similar setting that should be able to benchmark the results. 362 There were 2 factors that differed between the 2 groups. Specifically, there was more male in the 363 ID group and the time interval between second and third dose was 1 week longer in the ID 364 group. However, the immune responses at baseline before the third dose were comparable. 365 Female was reported to have higher antibody response to vaccines [37] and after severe COVID-366 19 [38]. The finding of later inferior neutralizing antibodies might be attributed to this gender 367 difference, specifically more male participants in ID cohort. This study chose to determine the 368 levels of functional neutralizing antibodies using the surrogate virus neutralization assay, rather 369 than standard live-virus neutralization assay. However, we used the high cut-off value at 80% of 370 sVNT in this study. Moreover, good correlations between sVNT and live-virus neutralization 371 have been exhibited elsewhere [18, 39-41]. The strengths of this study were reporting complete 372 solicited reactogenicity of all 100 participants with ID booster vaccination and multiple methods

were used for immunity analysis including anti-S-RBD, sVNT (wild type and delta strain) and
also CMI responses.

Intradermal AZD1222 booster vaccine in 2-dose-CoronaVac primed adult enhanced
comparable short-term immunity, but inferior 3-month immunogenicity, with intramuscular
administration. Reactogenicity was usually localized (erythema and pain) and less systemic than
intramuscular vaccine. Due to more rapid waning neutralizing antibody, dose-sparing strategy
with intradermal booster vaccination should be used in the setting of inadequate vaccine supply.

382 Acknowledgements

- 383 Thank you for all study teams for their assistance with the study.
- 384 Chulalongkorn University Health Service Center
- 385 Santhiti Dahlan, M.D., Preeyanuch Panchim, Ratchadaporn Bumrungpipattanaporn, RN,
- 386 Ampawan Sangchanpong, Wijitra Prayong
- 387 Department of Microbiology, Faculty of Medicine, Chulalongkorn University
- 388 Asst.Prof.Pokrath Hansasuta, M.D., Vichaya Ruenjaiman, PhD, Supapit Horpratum,
- 389 Jullada Thawilwang
- 390 Center of Excellence in Pediatric Infectious Diseases and Vaccines
- 391 Pintip Suchartlikitwong, M.D., Wipaporn Natalie Songtaweesin, M.D., Pathariya
- 392 Promsena, M.D., Monta Tawan, RN, Jitthiwa Athipunjapong, RN, Thutsanun
- 393 Meepuksom, RN, Angsumalin Sutjarit, RN, Juthamanee Moonwong, Rachaneekorn
- 394 Nadsasarn, Thidarat Jupimai, Pornpavee Nuncharoen, Sasiprapha Khamthi, Pathomchai
- 395 Amornrattanapaijit, Phattharapa Khamkhen,
- 396 National Center for Genetic Engineering and Biotechnology (BIOTEC)
- Anan Jongkaewwattana, PhD, Kirana Yoohat, Channarong Seepiban, Jaraspim Narkpuk,
 Thorntun Deangphare,
- 399 Clinical Research Laboratory, Faculty of Medicine, Chulalongkorn University
- 400 Palida Pingthaisong, Suwat Wongmueng
- 401 Faculty of Medicine, Thammasat University
- 402 Asst.Prof.Sira Nantapisal, M.D., Ph.D.
- 403
- 404 Funding

- 405 The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under
- 406 Health Research Platform (RA64/050), Chulalongkorn University.

407

408 **Conflict of interest**

- 409 The authors declare that they have no known competing financial interests or personal
- 410 relationships that could have appeared to influence the work reported in this paper.

412 **Table 1.** Baseline characteristics of participants receiving AZD1222 booster vaccine after 2-dose

413 CoronaVac in healthy adults

Characteristic	ID (N = 100)	IM (N = 100)	p-value
Gender			
• Female, n (%)	45 (45)	61 (61)	0.02^{+*}
Age (years)	46 (41-52)	45 (34-50)	0.08^{\ddagger}
BMI (kg/m^2)	24.8 (21.4-27.4)	24.1 (21.6-26.9)	0.37 [‡]
Underlying disease, n (%)	19 (19)	29 (29)	0.10 [†]
• Hypertension, n (%)	7 (7)	9 (9)	0.60^{\dagger}
• Dyslipidemia, n (%)	6 (6)	7 (7)	0.77^{\dagger}
• Diabetes mellitus, n (%)	6 (6)	3 (3)	0.31 [†]
• Allergic rhinitis, n (%)	1 (1)	2 (2)	0.56^{\dagger}
Duration of 2 nd doses of CoronaVac and	71(c5,7c)	$\mathcal{L}(\mathcal{L})$	0.00 2 [‡] *
AZD1222 (days)	71 (65-76)	66 (62-74)	0.002 [‡] *
Immunogenicity at baseline prior to			
booster			
• sVNT-delta (% inhibition), GM	22 4 (18 7 26 0)	17.0 (14.2.22.5)	$0.14^{\$}$
(95%CI)	22.4 (18.7-26.9)	17.9 (14.3-22.5)	0.14°
• sVNT-WT (%inhibition), GM			
(95%CI)	44.5 (40.6-48.7)	41.8 (37.1-47.1)	$0.41^{\$}$
• Anti-S-RBD (BAU/mL), GM			
(95%CI)	109.3 (95.4-125.1)	98.9 (85.8-113.9)	0.31 [§]
SNMO-specific T cell response	32 (14-56)	52 (40-84)	0.05
(SFU/10 ⁶ PBMCs)	(n = 20)	(n = 19)	0.05^{\ddagger}
RBD-specific B cell response	2 (0-10)	4 (0-16)	0.70†
(SFU/10 ⁶ PBMCs)	(n = 20)	(n = 19)	0.50^{\ddagger}

414 All data are reported as median (IQR), unless otherwise indicated.

- 415 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, BMI: Body
- 416 mass index, GM: Geometric mean, ID: intradermal, IM: intramuscular, IQR: interquartile range,
- 417 RBD: receptor binding domain, SNMO: Spike (S) nucleoprotein (N), membrane protein (M),
- 418 and open reading frame proteins (O) of SARS-CoV-2, sVNT-delta: Surrogate virus
- 419 neutralization test against delta strain, sVNT-WT: Surrogate virus neutralization test against wild
- 420 type
- 421 [†]Chi-square
- 422 [‡]Wilcoxon rank sum test
- 423 [§]Two sample independent t test
- 424 *p < 0.05

425 **Table 2.** Comparison of intradermal and intramuscular AZD1222 booster immunogenicity in

426 healthy adult completing 2-dose CoronaVac

		ID GM (95%CI)	IM GM (95%CI)	GM Ratio (95%CI)	
Day 1	4	N=50	N=100		
	Anti-S-RBD (BAU/mL)	2037.1	2043.2	0.99	
•	AIIII-S-KBD (BAU/IIIL)	(1770.9-2343.2)	(1824.5-2288.2)	(0.83-1.20)	
•	sVNT-Delta (% inhibition)	95.5	94.7	1.01	
•	svivi-Dena (% minoriton)	(94.2-96.8)	(92.4-97.1)	(0.97-1.04)	
•	sVNT-WT (% inhibition)	94.8	96.7	0.98	
•		(94.0-95.6)	(94.9-98.4)	(0.96-1.01)	
Day 2	28	N=50	N=24		
•	Anti-S-RBD (BAU/mL)	1084.9	1499.5	0.72	
•	And-S-KDD (DAO/IIIL)	(970-1213.4)	(1166.6-1927.4)	(0.57-0.91)	
•	sVNT-Delta (% inhibition)	93.7	88.5	1.06	
•	svivi Detta (70 minoritori)	(91.9-95.5)	(80.1-97.7)	(0.99-1.14)	
•	sVNT-WT (% inhibition)	93.7	91.5	1.02	
•		(92.1-95.4)	(85.9-97.4)	(0.98-1.08)	
Day 9	0	N=39	N=99		
•	Anti-S-RBD (BAU/mL)	744.6	909	0.82	
·		(650.1-852.9)	(802.1-1030.1)	(0.66-1.02)	
•	sVNT-Delta (% inhibition)	73.1	92.8	0.79	
•	svivi Detta (70 minoritori)	(66.7-80.2)	(90.2-95.4)	(0.73-0.85)	
•	sVNT-WT (% inhibition)	81.9	94.6	0.87	
·		(76.2-88.0)	(92.4-96.9)	(0.82-0.92)	
		% (95%CI)	% (95%CI)	% difference (95%CI)	
Day 1	4	N=50	N=100		
•	Anti-S-RBD ≥ 506 BAU/ml [†]	100.0	97.0	3.0	
-		(92.8-100.0)	(91.5-99.4)	(-0.3 to 6.3)	
•	sVNT-Delta \geq 80% inhibition	98.0	93.8	4.2	
		(89.1-99.9)	(86.9-97.6)	(-2.0 to 10.5)	
•	sVNT-WT ≥ 80% inhibition	100.0	95.8	4.2	
		(92.8-100.0)	(89.7-98.9)	(0.01 to 8.2)	
Day 2	28	N=50	N=24		
•	Anti-S-RBD ≥ 506 BAU/ml [†]	98.0	96.0	2.0	
-		(89.4-99.9)	(79.6-99.8)	(-6.6 to 10.6)	
٠	sVNT-Delta \geq 80% inhibition	98.0	91.7	6.3	

Page 25 of 40

	(89.4-99.9)	(73.0-98.9)	(-5.4 to 18.1)	
$_{\rm a}$ VNT WT > 80% inhibition	98.0	91.7	6.3	
	(89.4-99.9)	(73.0-98.9)	(-5.4 to 18.1)	
0	N=39	N=99	6.3 (-5.4 to 18.1) -4.4 (-18.9 to 10.2) -37.3	
Anti-S PRD > 506 BAU/ml^{\dagger}	79.5	83.8	-4.4	
	(63.5-90.7)	(75.1-90.5)	(-18.9 to 10.2)	
sVNT-Delta > 80% inhibition	52.6	89.9	-37.3	
	(35.8-69)	(82.2-95)	(-54.2 to -20.3)	
sVNT-WT > 80% inhibition	68.4	90.9	-22.5	
	(51.3-82.5)	(83.4-95.7)	(-38.3 to -6.7)	
	sVNT-WT ≥ 80% inhibition 0 Anti-S-RBD ≥ 506 BAU/ml [†] sVNT-Delta ≥ 80% inhibition sVNT-WT ≥ 80% inhibition	$sVNT-WT \ge 80\%$ inhibition 98.0 (89.4-99.9) 0 N=39 Anti-S-RBD ≥ 506 BAU/ml [†] 79.5 (63.5-90.7) $sVNT$ -Delta ≥ 80% inhibition 52.6 (35.8-69) $sVNT$ -WT ≥ 80% inhibition 68.4	sVNT-WT \ge 80% inhibition98.091.7(89.4-99.9)(73.0-98.9)0N=39Anti-S-RBD \ge 506 BAU/ml [†] 79.583.8(63.5-90.7)(75.1-90.5)sVNT-Delta \ge 80% inhibition52.689.9(35.8-69)(82.2-95)sVNT-WT \ge 80% inhibition68.4	

⁴²⁷

428 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, GM: Geometric

429 mean, ID: intradermal, IM: intramuscular, sVNT-delta: Surrogate virus neutralization test against

430 delta strain, sVNT-WT: Surrogate virus neutralization test against wild type

431 [†]Anti-S-RBD IgG 506 BAU/ml correlated with 80% vaccine efficacy as reported by Feng, et al

432 [17].

433





Figure 1. Solicited reactogenicity within 7 days of ID and IM AZD1222 booster after 2-dose 437


- 438 CoronaVac in healthy adult.
- 439 ID intradermal, IM intramuscular




442 Figure 2. Comparison of sVNT % inhibition against delta strain at day 0, 14, 28, and 90 of ID

- 443 and IM AZD1222 booster after 2-dose of CoronaVac in healthy adult.
- 444 ID: intradermal, IM: intramuscular, sVNT: Surrogate virus neutralization test
- 445

446 (A) SNMO-specific T cell response



448 (B) RBD-specific B cell response



450

- 451 Figure 3. ELISpot assay at day 0, day 28, and day 90 of ID and IM AZD1222 booster in healthy
- 452 adult completing 2-dose CoronaVac: (A) Interferon-γ ELISpot response to SNMO overlapping
- 453 peptides of SARS-CoV-2, (B) RBD-specific IgG ELISpot assay.
- 454 ID: intradermal, IM: intramuscular, RBD: receptor binding domain, SFU: spot forming unit,
- 455 SNMO: Spike (S) nucleoprotein (N), membrane protein (M), and open reading frame proteins
- 456 (O) of SARS-CoV-2

458 **Supplementary Table 1.** Solicited reactogenicity within 7 days of ID and IM AZD1222 booster

459 after 2-dose CoronaVac in healthy adult.

Reacto	ogenicity, n (%)	ID (N=100)	IM (N=100)	P-value
Local reac	togenicity	· · · · ·	× /	
Pain		43 (43)	82 (82)	<0.001*
• Mil	d	41 (41)	67 (67)	
• Mo	derate	2 (2)	13 (13)	
• Sev	vere	0	2 (2)	
	ration (days), dian (IQR)	2 (1-4)	3 (2-5)	0.12
Swelling		17 (17)	3 (3)	0.002*
• Mil	d	15 (15)	1 (1)	
• Mo	derate	1 (1)	2 (2)	
• Sev	vere	1 (1)	0	
	ration (days), dian (IQR)	6 (5-8)	4 (3-6)	0.28
Redness		53 (53)	3 (3)	<0.001*
• Mil	d	47 (47)	0 (0)	
• Mo	derate	5 (5)	2 (2)	
• Sev	vere	1 (1)	1 (1)	
	ration (days), dian (IQR)	4 (3-6)	5 (1-6)	0.35
Systemic r	eactogenicity			
Fever (BT	≥38°C)	0	27 (27)	NA
• Mil	d	0	10 (10)	
• Mo	derate	0	12 (12)	
• Sev	vere	0	5 (5)	
	ration (days), dian (IQR)	-	2 (1-2)	NA
Feverish		18 (18)	37 (37)	0.003*
• Mil	d	16 (16)	27 (27)	
• Mo	derate	2 (2)	10 (10)	
	ration (days), dian (IQR)	1 (1-2)	1 (1-2)	0.93
Headache		27 (27)	64 (64)	<0.001*
• Mil	d	17 (17)	37 (37)	
• Mo	derate	10 (10)	24 (24)	

Page 31 of 40

• Severe	0	3 (3)	
• Duration (days),	2 (1-2)	2 (1-3)	0.15
median (IQR)			
Fatigue	40 (40)	68 (68)	<0.001*
• Mild	36 (36)	42 (42)	
• Moderate	4 (4)	22 (22)	
• Severe	0 (0)	4 (4)	
• Duration (days),	1 (1-2)	2 (2-3)	0.61
median (IQR)			
Myalgia	30 (30)	69 (69)	<0.001*
• Mild	27 (27)	35 (35)	
Moderate	3 (3)	31 (31)	
• Severe	0 (0)	3 (3)	
• Duration (days),	2 (2-3)	2 (2-3)	0.60
median (IQR)			
Arthralgia	12 (12)	21 (21)	0.09
• Mild	8 (8)	15 (15)	
• Moderate	4 (4)	5 (5)	
• Severe	0 (0)	1 (1)	
• Duration (days),	2 (2-3)	2 (1-2)	0.06
median (IQR)			
Vomiting	0	4 (4)	NA
• Mild	0	4 (4)	
• Moderate	0	0 (0)	
• Severe	0	0 (0)	
• Duration (days),	0	1 (1-1)	NA
median (IQR)			
Diarrhea	9 (9)	12 (12)	0.49
• Mild	8 (8)	11 (11)	
Moderate	1 (1)	1 (1)	
• Duration (days),	1 (1-3)	1 (1-2)	0.43
median (IQR)			

460

461 ID: intradermal, IM: intramuscular

462 * p < 0.05



464



465

466 **Supplementary Figure 1.** Photography of local reactogenicity in participants receiving

467 intradermal AZD1222 booster after completing 2-dose CoronaVac: (A) local reactogenicity in

468 participants: i-ii) erythematous patch at injection site at day 4, iii) residual post inflammatory

- 469 hyperpigmented macule and iv) erythematous patch at injection site at day 28 and (B) a serial
- 470 photography day 1-7 in single participant: Day 1 erythematous patch at injection site, Day 2
- 471 central swelling on erythematous patch, Day 3-6 blister forming at central of erythematous patch,
- 472 and Day 7 dry blister with necrotic crust on erythematous base.

473 References

- 474 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from:
- 475 https://covid19.who.int/. Accessed date 28 November, 2021.
- 476 2. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness
- 477 of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med 2021.
- 478 https://doi.org/10.1056/NEJMoa2107715
- 479 3. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.
- 480 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
- 481 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg
- 482 Health Am 2021:100025. https://doi.org/10.1016/j.lana.2021.100025
- 483 4. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T,
- 484 Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern
- than natural infection. Lancet Infect Dis 2021. https://doi.org/10.1016/S1473-3099(21)00568-5
- 486 5. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
- 487 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
- 488 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-
- 489 inferiority trial. Lancet 2021;398:856-69. https://doi.org/10.1016/S0140-6736(21)01694-9
- 490 6. Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F, et al. Heterologous
- 491 ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses
- 492 among Health Care Workers. Vaccines (Basel) 2021;9. https://doi.org/10.3390/vaccines9080857
- 493 7. Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination:
- 494 A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag Healthc Policy
- 495 2021;14:2079-87. https://doi.org/10.2147/RMHP.S309707

- 496 8. Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques,
- 497 Challenges, and Prospects. Vaccines (Basel) 2020;8. https://doi.org/10.3390/vaccines8030534
- 498 9. Egunsola O, Clement F, Taplin J, Mastikhina L, Li JW, Lorenzetti DL, et al.
- 499 Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines:
- 500 A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2035693.
- 501 https://doi.org/10.1001/jamanetworkopen.2020.35693
- 502 10. World Health O. Polio vaccines: WHO position paper, March 2016-recommendations.
- 503 Vaccine 2017;35:1197-9. https://doi.org/10.1016/j.vaccine.2016.11.017
- 504 11. World Health O. WHO Expert Consultation on Rabies. Second report. World Health
- 505 Organ Tech Rep Ser 2013:1-139, back cover.
- 506 12. World Health O. Rabies vaccines: WHO position paper, April 2018 Recommendations.
- 507 Vaccine 2018;36:5500-3. https://doi.org/10.1016/j.vaccine.2018.06.061
- 508 13. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.
- 509 Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273
- 510 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv
- 511 2021:2021.07.27.21261116. https://doi.org/10.1101/2021.07.27.21261116
- 512 14. Intapiboon PS, P.; Ongarj, J.; Surasombatpattana, S.; Uppanisakorn, S.;
- 513 Mahasirimongkol, S.; Sawaengdee, W.; Phumiamorn, S.; Sapsutthipas, S.; Sangsupawanich, P.;
- 514 Chusri, S.; Pinpathomrat, N. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
- 515 Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
- 516 Vaccines 2021. https://doi.org/10.3390/vaccines9121375

- 517 15. Singhatiraj E, Pongpirul K, Jongkaewwattana A, Hirankarn N. Intradermal ChAdOx1
- 518 Vaccine Following Two CoronaVac Shots: A Case Report. Vaccines 2021;9:990.
- 519 https://doi.org/10.3390/vaccines9090990
- 520 16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et
- al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med
- 522 2020;26:1033-6. https://doi.org/10.1038/s41591-020-0913-5
- 523 17. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
- against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021.
- 525 https://doi.org/10.1038/s41591-021-01540-1
- 526 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
- 527 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
- 528 interaction. Nat Biotechnol 2020;38:1073-8. https://doi.org/10.1038/s41587-020-0631-z
- 529 19. U.S. Department of Health and Human Services F, CBER. Guidance for Industry
- 530 Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive
- 531 Vaccine Clinical Trials September 2007 [Available from:
- 532 https://www.fda.gov/media/73679/download. Accessed date 30 November, 2021.
- 533 20. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
- against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 2021.
- 535 https://doi.org/10.1038/s41591-021-01540-1
- 536 21. Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, et al.
- 537 Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination A
- 538 systematic review and meta-analysis. Travel Med Infect Dis 2020;37:101868.
- 539 https://doi.org/10.1016/j.tmaid.2020.101868

540	22.	Roozen GVT,	Prins MLM,	van Binnendij	kR.	Hartog	Gd.	Kuipe	r VP	, Prins C	, et al.

- 541 Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273
- 542 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021.
- 543 https://doi.org/10.1101/2021.07.27.21261116
- 544 23. Noh JY, Jeong HW, Kim JH, Shin EC. T cell-oriented strategies for controlling the
- 545 COVID-19 pandemic. Nat Rev Immunol 2021. https://doi.org/10.1038/s41577-021-00625-9
- 546 24. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al.
- 547 Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific
- 548 Immune Response. Front Immunol 2021;12:645210. https://doi.org/10.3389/fimmu.2021.645210
- 549 25. Jahnmatz P, Sundling C, Makower B, Sonden K, Farnert A, Ahlborg N. Multiplex

analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot. J

551 Immunol Methods 2020;478:112715. https://doi.org/10.1016/j.jim.2019.112715

- 552 26. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of
- 553 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2
- 554 mRNA Vaccine. Front Immunol 2021;12:740708. https://doi.org/10.3389/fimmu.2021.740708
- 555 27. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of
- 556 SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months
- 557 after the infection. Med (N Y) 2021;2:281-95 e4. https://doi.org/10.1016/j.medj.2021.02.001
- 558 28. Angsuwatcharakon P, Ratananpinit N, Yoksan S, Saengseesom W, Sriaksorn R,
- 559 Raksahket N, et al. Immunogenicity and safety of two-visit, intradermal pre-exposure rabies
- 560 prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis
- 561 vaccine in children living in rabies and Japanese encephalitis endemic country. Vaccine
- 562 2020;38:5015-20. https://doi.org/10.1016/j.vaccine.2020.05.054

- 563 29. Fritz TM, Trueb RM. [BCG ulcer. Rapid healing with topical INH powder]. Hautarzt
- 564 2002;53:816-8. https://doi.org/10.1007/s00105-002-0367-3
- 565 30. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and
- 566 intramuscular administration of hepatitis B vaccine in neonates. Indian J Gastroenterol
- 567 2001;20:94-6.
- 568 31. Blanchet K, Mallard G, Moret E, Sun J. Sanctioned countries in the global COVID-19
- 569 vaccination campaign: the forgotten 70. Confl Health 2021;15:69.
- 570 https://doi.org/10.1186/s13031-021-00404-2
- 571 32. Perry M, Akbari A, Cottrell S, Gravenor MB, Roberts R, Lyons RA, et al. Inequalities in
- 572 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales,
- 573 UK. Vaccine 2021. https://doi.org/10.1016/j.vaccine.2021.09.019
- 574 33. Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in
- 575 Brazilian elderly. Rev Bras Epidemiol 2021;24:e210041. https://doi.org/10.1590/1980-
- 576 549720210041
- 577 34. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
- 578 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus
- 579 Pandemic (COVID-19): Our World in Data; 2020 [cited 2021 26 sep 2021]. Available from:
- 580 https://ourworldindata.org/covid-vaccinations. Accessed date 26 September, 2021.
- 581 35. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused
- review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int
- 583 Immunopharmacol 2021;100:108162. https://doi.org/10.1016/j.intimp.2021.108162
- 584 36. Schweiger M. Intradermal covid-19 vaccination could solve supply problems. BMJ
- 585 2021;374:n1980. https://doi.org/10.1136/bmj.n1980

- 586 37. Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences
- 587 and age. Womens Health (Lond) 2021;17:17455065211022262.
- 588 https://doi.org/10.1177/17455065211022262
- 589 38. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG
- antibody between male and female COVID-19 patients: A possible reason underlying different
- 591 outcome between sex. J Med Virol 2020;92:2050-4. https://doi.org/10.1002/jmv.25989
- 592 39. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple
- 593 protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 2020;5.
- 594 https://doi.org/10.1172/jci.insight.142362
- 595 40. Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke GJ, Yerly S, et al. Validation and
- 596 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg
- 597 Microbes Infect 2020;9:2394-403. https://doi.org/10.1080/22221751.2020.1835448
- 598 41. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, et al.
- 599 Evaluation of a commercially-available surrogate virus neutralization test for severe acute
- 600 respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis
- 601 2021;99:115294. https://doi.org/10.1016/j.diagmicrobio.2020.115294